EP3962477A4 - Nanostructures comprising cobalt porphyrin-phospholipid conjugates and polyhistidine-tags - Google Patents

Nanostructures comprising cobalt porphyrin-phospholipid conjugates and polyhistidine-tags Download PDF

Info

Publication number
EP3962477A4
EP3962477A4 EP20798748.8A EP20798748A EP3962477A4 EP 3962477 A4 EP3962477 A4 EP 3962477A4 EP 20798748 A EP20798748 A EP 20798748A EP 3962477 A4 EP3962477 A4 EP 3962477A4
Authority
EP
European Patent Office
Prior art keywords
polyhistidine
nanostructures
tags
cobalt porphyrin
phospholipid conjugates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP20798748.8A
Other languages
German (de)
French (fr)
Other versions
EP3962477A1 (en
Inventor
Jonathan Lovell
Shuai SHAO
Jumin GENG
Wei-Chiao Huang
Shwu-Maan Lee
Charles Richter King
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Path
Research Foundation of State University of New York
Original Assignee
Path
Research Foundation of State University of New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/399,581 external-priority patent/US11207421B2/en
Application filed by Path, Research Foundation of State University of New York filed Critical Path
Publication of EP3962477A1 publication Critical patent/EP3962477A1/en
Publication of EP3962477A4 publication Critical patent/EP3962477A4/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/41—Porphyrin- or corrin-ring-containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0225—Spirochetes, e.g. Treponema, Leptospira, Borrelia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A61K2039/55594—Adjuvants of undefined constitution from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • AIDS & HIV (AREA)
  • Dispersion Chemistry (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP20798748.8A 2019-04-30 2020-04-29 Nanostructures comprising cobalt porphyrin-phospholipid conjugates and polyhistidine-tags Pending EP3962477A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16/399,581 US11207421B2 (en) 2015-04-16 2019-04-30 Nanostructures comprising cobalt porphyrin-phospholipid conjugates and polyhistidine-tags
PCT/US2020/030537 WO2020223395A1 (en) 2019-04-30 2020-04-29 Nanostructures comprising cobalt porphyrin-phospholipid conjugates and polyhistidine-tags

Publications (2)

Publication Number Publication Date
EP3962477A1 EP3962477A1 (en) 2022-03-09
EP3962477A4 true EP3962477A4 (en) 2023-05-03

Family

ID=73028666

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20798748.8A Pending EP3962477A4 (en) 2019-04-30 2020-04-29 Nanostructures comprising cobalt porphyrin-phospholipid conjugates and polyhistidine-tags

Country Status (6)

Country Link
EP (1) EP3962477A4 (en)
JP (1) JP2022530539A (en)
CN (1) CN114502159A (en)
AU (1) AU2020266139A1 (en)
CA (1) CA3138856A1 (en)
WO (1) WO2020223395A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023183287A2 (en) * 2022-03-21 2023-09-28 The University Of North Carolina At Chapel Hill Composite bioactive compositions and applications thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016168817A1 (en) * 2015-04-16 2016-10-20 The Research Foundation For The State University Of New York Nanostructures comprising cobalt porphyrin-phospholipid conjugates and polyhistidine-tags
WO2017176833A1 (en) * 2016-04-05 2017-10-12 The Research Foundation For The State University Of New York Novel pneumococcal vaccine formulations
WO2018170260A1 (en) * 2017-03-15 2018-09-20 Modernatx, Inc. Respiratory syncytial virus vaccine

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016168817A1 (en) * 2015-04-16 2016-10-20 The Research Foundation For The State University Of New York Nanostructures comprising cobalt porphyrin-phospholipid conjugates and polyhistidine-tags
WO2017176833A1 (en) * 2016-04-05 2017-10-12 The Research Foundation For The State University Of New York Novel pneumococcal vaccine formulations
WO2018170260A1 (en) * 2017-03-15 2018-09-20 Modernatx, Inc. Respiratory syncytial virus vaccine

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KEVIN A. CARTER ET AL: "Functionalization of cobalt porphyrin-phospholipid bilayers with his-tagged ligands and antigens", NATURE COMMUNICATIONS, vol. 5, no. 1, 3 April 2014 (2014-04-03), XP055528852, DOI: 10.1038/ncomms4546 *
See also references of WO2020223395A1 *
SHAO SHUAI ET AL: "Functionalization of cobalt porphyrin-phospholipid bilayers with his-tagged ligands and antigens", NATURE CHEMISTRY, vol. 7, no. 5, 20 April 2015 (2015-04-20), London, pages 438 - 446, XP093034593, ISSN: 1755-4330, Retrieved from the Internet <URL:http://www.nature.com/articles/nchem.2236> DOI: 10.1038/nchem.2236 *

Also Published As

Publication number Publication date
CN114502159A (en) 2022-05-13
JP2022530539A (en) 2022-06-29
AU2020266139A1 (en) 2021-12-02
WO2020223395A1 (en) 2020-11-05
EP3962477A1 (en) 2022-03-09
CA3138856A1 (en) 2020-11-05

Similar Documents

Publication Publication Date Title
EP3626825A4 (en) Anti-cdh6 antibody and anti-cdh6 antibody-drug conjugate
EP4032892A4 (en) Camptothecin derivative and conjugate thereof
EP3758729A4 (en) Il-15 conjugates and uses thereof
EP3801634A4 (en) Tumor microenvironment-activated drug-binder conjugates, and uses related thereto
EP3572428A4 (en) Anti-gpr20 antibody and anti-gpr20 antibody-drug conjugate
EP3283056A4 (en) Nanostructures comprising cobalt porphyrin-phospholipid conjugates and polyhistidine-tags
EP3752534A4 (en) Glypican 3 antibodies and conjugates thereof
EP3695852A4 (en) Anti-mesothelin antibody and antibody-drug conjugate thereof
EP4076448A4 (en) Fluoroalkyl-oxadiazoles and uses thereof
EP3903825A4 (en) Bi-ligand drug conjugate and use thereof
EP3946320A4 (en) Hsp90-binding conjugates and formulations thereof
EP4043034A4 (en) Lysosome-targeting antibody-drug conjugate and application thereof
EP3820467A4 (en) Antibody-alk5 inhibitor conjugates and their uses
EP3843736A4 (en) Isoquinoline-steroid conjugates and uses thereof
EP3876973A4 (en) Interleukin 10 conjugates and uses thereof
EP3941946A4 (en) Claudin-6 antibodies and drug conjugates
EP3723811A4 (en) Hsp90-targeting conjugates and formulations thereof
EP4037670A4 (en) 5-fluoronicotinamide derivatives and uses thereof
EP4069297A4 (en) Anti-avb6 antibodies and antibody-drug conjugates
EP4058486A4 (en) Antibody-payload conjugates with enhanced delivery domain and uses thereof
EP3994150A4 (en) Anti-tissue factor antibody-drug conjugates and related methods
EP3958909A4 (en) Anti-cd117 antibody-drug conjugates and uses thereof
EP4011898A4 (en) 3-hydroxy-5-pregnane-20-one derivative and use thereof
EP4051711A4 (en) Anti-cd45 antibodies and conjugates thereof
EP3638306A4 (en) Antibody-drug conjugates containing anti-globo h antibodies and uses thereof

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20211130

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40069453

Country of ref document: HK

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61K0031409000

Ipc: A61K0047690000

A4 Supplementary search report drawn up and despatched

Effective date: 20230405

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 31/18 20060101ALI20230330BHEP

Ipc: A61P 31/14 20060101ALI20230330BHEP

Ipc: A61K 38/41 20060101ALI20230330BHEP

Ipc: A61K 38/16 20060101ALI20230330BHEP

Ipc: A61K 31/409 20060101ALI20230330BHEP

Ipc: A61K 47/54 20170101ALI20230330BHEP

Ipc: A61K 47/69 20170101AFI20230330BHEP